Journal
CANCER LETTERS
Volume 318, Issue 1, Pages 76-85Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.12.003
Keywords
Ovarian cancer; Epigenetics; DNA methylation; Biomarkers; Microarray analysis
Categories
Funding
- NHMRC
- Cancer Australia Fellowship
- Cancer Institute NSW
- Gynaecological Oncology Fund
- Australian Postgraduate Award
Ask authors/readers for more resources
To identify epigenetic-based biomarkers for diagnosis of ovarian cancer we performed MeDIP-Chip in A2780 and CaOV3 ovarian cancer cell lines. Validation by Sequenom massARRAY methylation analysis confirmed a panel of six gene promoters (ARMCX1, ICAM4, LOC134466, PEG3, PYCARD & SGNE1) where hypermethylation discriminated 27 serous ovarian cancer clinical samples versus 12 normal ovarian surface epithelial cells (OSE) (ROC of 0.98). Notably, CpG sites across the transcription start site of a potential long-intergenic non-coding RNA (lincRNA) gene (LOC134466), was shown to be hypermethylated in 81% of serous EOC and could differentiate tumours from OSE (p < 0.05). We propose that this potential biomarker panel holds great promise as a diagnostic test for high-grade (Type II) serous ovarian cancer. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available